With Glaxosmithkline plc (GSK) having sailed through an FDA advisory panel meeting July 14 centered on its belantamab mafodotin (belantamab), an antibody-drug conjugate (ADC) for multiple myeloma (MM), others in the B-cell maturation antigen (BCMA) space such as Legend Biotech Corp. are further piquing Wall Street’s interest.
American depositary shares in CAR T-focused Legend Biotech Corp. (NASDAQ:LEGN), offered in a red hot IPO at $23 each, took off Friday, rising 60.9% to close at $37 per share. Other offerings June 5, a buoyant day for U.S. markets after a surprising drop in unemployment, raised $154 million for cellular trafficking specialist Applied Molecular Transport Inc. and $90 million for Calliditas Therapeutics AB, the developer of an oral formulation of the corticosteroid budesonide.
American depositary shares in CAR T-focused Legend Biotech Corp. (NASDAQ:LEGN), offered in a red hot IPO at $23 each, took off Friday, rising 60.9% to close at $37 per share. Other offerings June 5, a buoyant day for U.S. markets after a surprising drop in unemployment, raised $154 million for cellular trafficking specialist Applied Molecular Transport Inc. and $90 million for Calliditas Therapeutics AB, the developer of an oral formulation of the corticosteroid budesonide.
BEIJING – Legend Biotech Corp., headquartered in Somerset, N.J., filed with the U.S. SEC last week plans to raise up to $100 million to advance its BCMA-targeting CAR T candidate, LCAR-B38M, by listing on Nasdaq. Legend confidentially submitted a draft registration statement to the regulators in March.